Primaquine dispersible

Owned by Tridem Pharma S.A.S
B&O/Tridem Pharmaceutical

Product vision
  • Product targeting prevention of relapse for P. vivax
  • Product for transmission reduction
Dosing
  • 2.5mg and 5mg Primaquine dispersible tablets, 14-day course in all transmission settings to prevent relapse, treat P. vivax or P. ovale malaria in children and adults
  • Reducing the transmissibility of treated P. falciparum infections: In low-transmission areas, give a single dose of 0.25 mg/kg primaquine with ACT to patients with P. falciparum malaria (except pregnant women, infants aged < 6 months and women breastfeeding infants aged < 6 months) to reduce transmission
Efficacy
  • WHO guidelines recommend primaquine to prevent relapse, treat P. vivax or P. ovale malaria in children and adults (except pregnant women, infants aged < 6 months, women breastfeeding infants aged < 6 months, women breastfeeding older infants unless they are known not to be G6PD deficient, and people with G6PD deficiency)
Key features
  • Would be first child friendly dispersible formulation
Challenges
  • Limited use in low transmission settings
Status
  • Prototype development
Next milestone
  • Bioequivalence study start
MMV Project Director
  • Pierre Hugo